Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Pancreaticobiliary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Pancreaticobiliary Neoplasm

Cancer Family

Pancreaticobiliary Neoplasm

CI-CAN-00000309Explore in graph →

Non-malignant1,204 active trials11 approved drugs92 evidence items

NCIt: C223357

Overview
Statistics
Survival
Genomics36
Variants & evidence92
Drugs43
Trials5004
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (277)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 277 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.
· J Gastrointest Oncol · 2017 · PMID 28480077 · validated civic_curation pubmed
Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.
· J Gastrointest Oncol · 2016 · PMID 28078132 · validated civic_curation pubmed
Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
· Ecancermedicalscience · 2014 · PMID 25435907 · validated civic_curation pubmed
Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
· J Gastrointest Cancer · 2016 · PMID 26687137 · validated civic_curation pubmed
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
· Anticancer Res · 2011 · PMID 21508395 · validated civic_curation pubmed
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
· J Natl Compr Canc Netw · 2017 · PMID 28874593 · validated civic_curation pubmed
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.

Showing 226–250 of 277 publications

← Previous
1
…
9
10
11
12
Next →

· Clin Cancer Res · 2019 · PMID 31068372 · validated civic_curation pubmed

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.

· NPJ Precis Oncol · 2019 · PMID 31453370 · validated civic_curation pubmed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

· Cancer Discov · 2018 · PMID 29903880 · validated civic_curation pubmed

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.

· JCO Precis Oncol · 2022 · PMID 35005993 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

· J Clin Oncol · 2011 · PMID 22025163 · validated civic_curation pubmed

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

· J Clin Oncol · 2011 · PMID 21189378 · validated civic_curation pubmed

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

· Cancer Biol Ther · 2018 · PMID 27466707 · validated civic_curation pubmed

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.

· Cold Spring Harb Mol Case Stud · 2019 · PMID 31160355 · validated civic_curation pubmed

Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature.

· J Clin Pathol · 2023 · PMID 34583947 · validated civic_curation pubmed

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

· Cancer Cell · 2016 · PMID 26725216 · validated civic_curation pubmed

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

· Cancer Discov · 2016 · PMID 27231123 · validated civic_curation pubmed

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

· Oncotarget · 2014 · PMID 25216528 · validated civic_curation pubmed

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis.

· Genet Mol Res · 2015 · PMID 26662432 · validated civic_curation pubmed

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

· Clin Cancer Res · 2005 · PMID 16243825 · validated civic_curation pubmed

Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.

· J Cell Mol Med · 2012 · PMID 22004109 · validated civic_curation pubmed

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.

· Cancer Sci · 2010 · PMID 20088962 · validated civic_curation pubmed

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

· Target Oncol · 2016 · PMID 26668065 · validated civic_curation pubmed

Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis.

· J Natl Cancer Inst · 2002 · PMID 11792751 · validated civic_curation pubmed